Invasive fungal infections (IFI) cause devastating morbidity and mortality, with the number of IFIs more than tripling since 1979. Our laboratories were the first to demonstrate that radiolabeled microorganism-specific monoclonal antibodies are highly effective for treatment of experimental fungal, bacterial and viral infections. Later we proposed to utilize surface expressed pan-antigens shared by major IFI-causing pathogens such as beta-glucans as RIT targets. Here we evaluated in vivo RIT targeting beta-glucan in Blastomyces dermatitidis which causes serious infections in immunocompromised and immunocompetent individuals and in companion dogs. B. dermatitidis cells were treated with the 400-2 antibody to (1â3)-β-glucans radiolabeled with the beta-emitter 177Lutetium ((177)Lu) and alpha-emitter 213Bismuth ((213)Bi) and the efficacy of cell kill was determined by colony forming units (CFUs). To determine the antigen-specific localization of the 400-2 antibody in vivo, C57BL6 mice were infected intratracheally with 2 à 10(5) B. dermatitidis cells and given (111)In-400-2 antibody 24 h later. To evaluate the killing of B. dermatitidis cells with RIT, intratracheally infected mice were treated with 150 μCi (213)Bi-400-2 and their lungs analyzed for CFUs 96 h post-infection. (213)Bi-400-2 proved to be more effective in killing B. dermatitidis cells in vitro than (177)Lu-400-2. Three times more (111)In-400-2 accumulated in the lungs of infected mice, than in the non-infected ones. (213)Bi-400-2 lowered the fungal burden in the lungs of infected mice more than 2 logs in comparison with non-treated infected controls. In conclusion, our results demonstrate the ability of an anti-(1-3)-beta-D-glucan antibody armed with an alpha-emitter (213)Bi to selectively kill B. dermatitidis cells in vitro and in vivo. These first in vivo results of the effectiveness of RIT targeting pan-antigens on fungal pathogens warrant further investigation.
Radioimmunotherapy of Blastomycosis in a Mouse Model With a (1â3)-β-Glucans Targeting Antibody.
利用 (1→3)-β-葡聚糖靶向抗体对小鼠芽生菌病进行放射免疫治疗
阅读:3
作者:Helal Muath, Allen Kevin J H, van Dijk Bruce, Nosanchuk Joshua D, Snead Elisabeth, Dadachova Ekaterina
| 期刊: | Frontiers in Microbiology | 影响因子: | 4.500 |
| 时间: | 2020 | 起止号: | 2020 Feb 7; 11:147 |
| doi: | 10.3389/fmicb.2020.00147 | 种属: | Mouse |
| 研究方向: | 免疫/内分泌 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
